Umberto Peretti
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants.
Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Published: April 16, 2024
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: March 21, 2024
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma.
Journal: Clinical and translational radiation oncology
Published: July 05, 2023
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: May 22, 2023
The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis.
Journal: Journal of gastrointestinal cancer
Published: February 15, 2023
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Journal: Cancer chemotherapy and pharmacology
Published: February 05, 2023
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Journal: British journal of cancer
Published: April 15, 2022
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.
Journal: Cancer treatment reviews
Published: December 01, 2021
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Journal: Cancer treatment reviews
Published: April 21, 2021
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
Journal: ESMO open
Published: April 08, 2021
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus nab-paclitaxel for Advanced Pancreatic Adenocarcinoma.
Journal: Frontiers in oncology
Published: March 31, 2021
Last Updated: 09/26/2026